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Abstract 
 
 
Background: Chromosome copy gain, loss and LOH involving most chromosomes have 
been reported in many cancers, but less is known about chromosome instability in 
premalignant conditions. 17p LOH and DNA content abnormalities have been previously 
reported to predict progression from Barrett’s esophagus (BE) to esophageal 
adenocarcinoma (EA). Here, we evaluated genome-wide chromosomal instability in 
multiple stages of BE and EA in whole biopsies. Methods: 42 patients were selected to 
represent different stages of progression from BE to EA. Whole BE or EA biopsies were 
minced, aliquots processed for flow cytometry and genotyped with a paired constitutive 
control for each patient using 33,423 SNPs. Results: Copy gains, losses, and LOH 
increased in frequency and size between early and late stage BE (p<0.001), with SNP 
abnormalities increasing from <2% to >30% in early and late stages, respectively.  A set 
of statistically significant events were unique to either early, late or both stages, including 
previously reported and novel abnormalities. The total number of SNP alterations was 
highly correlated with DNA content aneuploidy and was sensitive and specific to identify 
patients with concurrent EA (empirical ROC AUC=0.91). Conclusions: With the 
exception of 9p LOH, most copy gains, losses, and LOH detected in early stages of BE 
were smaller than those detected in later stages, and few chromosomal events were 
common in all stages of progression. Measures of chromosomal instability can be 
quantified in whole biopsies using SNP-based genotyping and have potential to be an 
integrated platform for cancer risk stratification in BE. 
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Introduction 
 
Genomic instability has been hypothesized to play a crucial role in development of 
cancer for decades(1), and there is substantial evidence to support this hypothesis. 
Numerous studies have investigated genome-wide copy number changes and LOH(2-5) 
in EA and other cancers, including renal cell(6), colon(7, 8), cervical(9), pancreas(10), 
lung(11, 12), and glioblastoma(13). These studies have reported that the cancer genome 
acquires extensive chromosomal changes during neoplastic progression from a normal 
cell to cancer. Many of these alterations confer a selective advantage for the cancers 
(“drivers”) relative to normal cells, but others appear to be hitchhikers that are 
evolutionarily neutral (“passengers”)(14). Few studies have utilized SNP-based 
technologies to evaluate genome-wide copy number and LOH in premalignant stages of 
neoplastic progression compared to those in cancer(15-17). Characterization of 
premalignant conditions is important to understand the biology of neoplastic progression 
as well as to identify potential targets for cancer prevention and to develop methods for 
cancer risk stratification or early diagnosis of an asymptomatic cancer.  
 
The incidence of esophageal adenocarcinoma (EA) is rising more rapidly than any other 
cancer in the US(18, 19).  EA is typically detected at an advanced stage in which it is 
rapidly fatal with mortality greater than 80%(20, 21). Barrett’s esophagus (BE) is a 
condition that develops in a subset of patients with chronic gastroesophageal reflux 
disease in which the normal squamous epithelium of the esophagus is replaced by 
intestinal metaplasia(22). Although BE is the only known precursor of EA, most patients 
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with BE die of causes unrelated to BE or EA(23, 24). Further, recent evidence suggests 
that in most cases BE appears to be a successful adaptation to a harsh intraesophageal 
environment with chronic acid and bile reflux associated with erosion, ulceration, 
reactive oxygen species and oxidative damage(25-28). Thus, there is a need for 
biomarkers that can distinguish common, benign BE patients for whom surveillance can 
be safely prolonged, rare cases that will progress and therefore merit careful surveillance 
or intervention to prevent EA, and patients who require early detection because they have 
already developed a small EA that cannot be visualized endoscopically.  
 
BE is one of the best models of human intraepithelial neoplasia because the premalignant 
epithelium can be safely visualized and biopsied so that genomic changes can be 
compared in different stages of neoplastic evolution and then studied longitudinally by 
endoscopic biopsy surveillance for EA risk management(29, 30). Genetic progression 
models and longitudinal studies of oral leukoplakia have also shown successes in using 
somatic genetic biomarkers for risk stratification in head and neck cancer(31-35). This is 
in contrast to many other premalignant conditions that are typically removed when 
detected, such as colonic adenomas, or are unable to be systematically sampled for 
biopsy examination over time because of limited accessibility or potential clinical 
complications. Studies of BE indicate that inactivation of CDKN2A by loss of 
heterozygosity (LOH), methylation and/or mutation is selected as an early event that 
predisposes to large clonal expansions in the BE segment(36-38). Inactivation of TP53 by 
mutation and LOH is subsequently selected, typically in a CDKN2A deficient 
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background, and predisposes to progression to increased 4N fractions (G2/tetraploidy), 
aneuploidy and EA(14, 29, 32-34, 38-42).   
  
We reported recently in a 10-year prospective cohort study that a panel of chromosome 
instability biomarkers, including LOH spanning the CDKN2A and TP53 loci on 
chromosome arms 9p and 17p, and DNA content abnormalities (increased 4N, and 
aneuploidy) identified a high-risk patient subset that had a 79% five-year cumulative 
incidence of EA and a low-risk subset with a 0% cumulative EA incidence to nearly eight 
years of follow-up after their baseline endoscopic biopsy surveillance(43). This and other 
studies support the hypothesis that progressive chromosomal instability and clonal 
evolution drive progression from a benign premalignant state to cancer(29, 32-34, 42, 
44). However, it has been difficult to combine these biomarkers into a single platform for 
clinical use because various and complex sample processing methods are required, 
including flow cytometric cell sorting and multiple research assays for LOH detection. 
Further, regions of LOH evaluated in these studies were based on low density 
microsatellite polymorphisms(45-47). In addition, genome-wide studies of chromosomal 
instability in EA have identified common regions of copy gain, loss, copy neutral LOH, 
and a small number of homozygous deletions(2), but these events have not been 
quantified in early stages of progression in BE.   
 
Here, we evaluate genome-wide copy gain, loss, LOH and assess SNP-based 
quantification of aneuploidy in a cross-sectional study of patients representing different 
stages of progression from early BE metaplasia to advanced EA using paired samples 
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with Illumina multisample 33K SNP BeadChips. Selection of patients and biopsies in this 
study was guided by previous extensive characterization of the Seattle Barrett’s 
esophagus cohort, which allowed more precise estimation of risk based on molecular 
characterization and more endoscopic follow-up data than are typically available.  
Chromosome alterations including genome-wide copy gain, loss, and LOH were 
evaluated and compared across the progression stages using whole, unpurified biopsies. 
Overall genomic instability was quantified relative to DNA content aneuploidy in the 
same biopsy to assess feasibility of using SNP-arrays as a common platform for 
biomarkers of EA risk.   
         
Material and Methods 
 
Study participants and biological samples 
Participants were enrolled in the Seattle Barrett’s Esophagus Study, which was approved 
by the Human Subjects Division of the University of Washington in 1983 and renewed 
annually thereafter with reciprocity from the Fred Hutchinson Cancer Research Center 
(FHCRC) Institutional Review Board from 1993 to 2001. Since 2001, the study has been 
approved by the FHCRC IRB with reciprocity from the University of Washington Human 
Subjects Division.  
Mucosal biopsies used in this cross sectional study were obtained from 42 patients using 
previously defined protocols for endoscopic mucosal biopsy and evaluation of surgical 
resection specimens(48, 49). A constitutive control sample from gastric tissue was 
collected for each of the 42 participants and used as the reference for paired LOH and 
copy number analysis. The 42 participants each had histologically diagnosed specialized 
 7
intestinal metaplasia and represented four different stages of neoplastic progression in 
Barrett’s esophagus defined by   
1. [BE Early] 12 surveillance endoscopic biopsies from 12 participants with 
Barrett’s esophagus who never developed DNA content abnormalities 
(aneuploidy or 4N fraction >6%), high-grade dysplasia, or EA during any follow-
up endoscopies (mean 118.3 months, range 59.2 to 182.6 months) and in whom 
no TP53 mutation or 17p LOH was detected at baseline (M:F=1:11, mean age 
58);   
2. [BE instability] 12 endoscopic biopsies from 12 participants with Barrett’s 
esophagus who developed a DNA content abnormality (aneuploidy and/or 
increased 4N) during surveillance (mean 104.5 months, range 42.2 to 208.3 
months) but in whom no TP53 mutation or 17p LOH  was detected at baseline 
(M:F=3:9, mean age 63). During this follow-up period, 6 of 12 participants had a 
diagnosis of high-grade dysplasia and one participant developed cancer after 14 
years. DNA content abnormalities and high-grade dysplasia are known risk factor 
for progression to EA(48);  
3. [Advanced BE] 10 Barrett’s mucosal biopsies within premalignant Barrett’s 
epithelium from 10 surgical resections in participants with  microscopic EAs, 
including nine intramucosal and one with superficial submucosal invasion 
detected during endoscopic surveillance (mean BE surveillance 21.1 months, 
range 4.2 to 42.3 months, M:F=2:8, mean age 63) and  
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4. [EA] 8 large esophageal adenocarcinoma specimens averaging 4.8 cm in diameter 
(range 1.5 cm to 9 cm) from the surgical resection specimens of 8 patients 
(M:F=0:8, mean age 75).  
DNA content flow cytometry to determine ploidy of BE/EA biopsies 
Whole biopsy specimens and gastric controls, including fresh/frozen endoscopic biopsies 
(n = 48) or surgical resection specimens (n=36), were processed. For the BE and EA 
samples, whole endoscopic biopsies (n=24) or surgical resection specimens (n=18) were 
minced in buffer used for preparing tissue for flow cytometry (146 mM NaCl, 10mM Tris 
Base (pH 7.5), 1 mM CaCl2, 0.5 mM MgSO4, 0.05% Bovine serum albumin (BSA), 21 
mM MgCl2, 0.2% Igepal CA-630 Sigma I3021 as previously described(50).  
Approximately 90ul of unfixed nuclei were saturated with DAPI (5 µg/ml, Accurate 
Chemical, Westbury, NY) and evaluated for DNA content on a Cytopeia inFlux flow 
cytometer (Seattle, WA). Listmode files were analyzed  using Multicycle (Phoenix Flow 
Systems, San Diego, CA)  as described previously(51, 52).  
 
SNP-based copy gain, loss, and LOH using Illumina Infinium technology 
DNA from the remaining minced tissue of each whole biopsy was extracted using 
standard Puregene DNA Isolation Kit as recommended by the manufacturer (Gentra 
Systems, Inc. Minneapolis, MN), and quantitated with the Quant-iT™ PicoGreen® 
dsDNA Assay Kit following manufacturers protocol (Invitrogen) on the CytoFluor II 
plate reader. DNA for SNP arrays was not purified by flow cytometry because this study 
is designed to identify abnormalities that ultimately may be assessed in whole biopsies 
without further purification in a clinical setting. Each sample was genotyped using a 
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Illumina 12-sample Human Hap300_Pool10 Beadchip targeting 33,423 SNP loci (33K 
SNP array) from the HumanHap300 BeadChip and processed at Illumina using standard 
multi-sample Infinium protocols and reagents according to manufacturer’s instructions. 
DNA (average 223.8ng input) was amplified, enzymatically fragmented, precipitated, 
resuspended in hybridization buffer, denatured, and hybridized to the BeadChip overnight 
at 48°C. After the overnight incubation, the BeadChip was washed, primer extended, and 
stained on a Tecan Genesis/EVO robot using a Tecan GenePaint slide processing system. 
After staining, BeadChips were washed and coated, then scanned using Illumina’s 
BeadArray Reader.  The probe intensity data were extracted and analyzed using 
Illumina's BeadStudio 3.1 software.  
 
Genotyping data consists of two channel intensity data corresponding to the two alleles. 
Data is generated as rectangular coordinates of the raw A versus raw B allele intensities. 
After normalization with BeadArray Reader, the genotyping data were transformed to a 
polar coordinate plot of normalized intensity R = Xnorm + Ynorm and allelic intensity 
ratio theta=(2/pi)* arctan (Ynorm / Xnorm), where Xnorm and Ynorm represent 
transformed normalized signals from alleles A and B for a particular locus. For each 
patient, a pair of normal gastric (reference) and a BE/EA sample (subject) was processed 
in paired mode, using default reference clustering. The B allele frequency parameter, 
based upon the theta values, is calculated for each locus as described previously (53).  
      
Statistical Methods 
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We examined the MA plots (signal intensity vs. signal ratio plot) for each sample and 
found no bias. Paired constitutive controls for each patient were used to ensure that all 
abnormalities detected were somatic lesions and not constitutive copy number variations 
that could arise when using a single reference sample for all patients(54, 55).  Paired 
sample analysis of BE or EA samples (defined as “sub”) paired with the control gastric 
sample (defined as “ref”) from each patient generated two parameters, the log-ratio 
log2(Rsub/Rref) and |dAlleleFreq sub-ref| that were used for copy number and LOH 
detection(53).  The |dAlleleFreq sub-ref| represents the absolute value of the difference in 
allele frequency between the subject (BE or EA) and reference (paired constitutive 
control) samples.  Since both samples are from the same patient, the difference of allele 
frequency at any given locus should be approximately zero except in regions exhibiting 
somatic chromosomal anomalies such as copy number differences or LOH.  Two stages 
of data analysis were performed in this study. The first identified copy gain, copy loss, 
and LOH for each chromosome arm. The second tested whether or not the frequency of a 
gain, loss or LOH identified in a given segment along the chromosome arm reached 
statistical significance across patients.  
 
Specifically, we defined the normal baseline copy number (2N) on each chromosome 
using |dAlleleFreq sub-ref|. After wavelet processing (see below) of |dAlleleFreq sub-ref|, 
regions with signal values including at least 10% contiguous SNPs on either chromosome 
arm with a |dAlleleFreq sub-ref| equal to zero were identified. These regions were used to 
set the baseline chromosome copy number (adjusted Log2(Rsub/Rref) to zero and was 
applied to specifically to that chromosome).  If a contiguous region of 10% of  SNPs 
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could not be found on a chromosome, then no adjustment was made for a baseline copy 
number. A wavelet method was used to smooth both copy number Log2(Rsub/Rref) and 
|dAlleleFreq sub-ref| signal values(56, 57).  Daubechies3 wavelets were used in this 
study, and array signal was decomposed to the second level with the wavelets and re-
constructed following dynamic thresholding (depending on the signal to noise ratio for 
that sample).  For a specific constitutive genotype “AB”, after above wavelet procedure 
processing (including thresholding), probes with Log2(Rsub/Rref) signal values that 
deviated from zero were identified as either copy gain (allelic imbalance, e.g. AAB or 
balanced, e.g. AABB) or loss (deletion or homozygous deletion). Probes with 
|dAlleleFreq sub-ref| which deviated from zero after wavelet processing including 
thresholding were identified to be LOH (allelic imbalance, e.g A and AAB or copy 
neutral LOH, e.g.AA).  Infrequently, there were a few noncontiguous probe signal levels 
that were more than four standard deviations from the mean signal of a chromosome 
arm.  Since some of those signal values could be smoothed out by wavelets, those signal 
values were included as lesions for that patient and subjected to consistency testing in the 
second stage of analysis.  A Kruskal-Wallis test was used to compare the median number 
of lesions and sizes of lesions in each group (Figure 1 and 2). For the size of events, we 
defined a gain, loss or LOH segment as continuous until there were at least two adjacent 
probes without that lesion. Thus, the boundaries of a lesion segment were defined by at 
least two or more probes without the lesion (Figure 2). Poisson regression was used to 
test the frequency of the lesion in each group (Figure 2). 
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In the second stage of analysis the significance of frequencies of lesions across the 
patients was tested. Copy number gain, loss, and LOH, were tested separately along the 
chromosome arms. Specifically for each of the three types of lesions, every chromosome 
arm was divided into 0.5Mb windows, although the last window may be smaller than 
0.5Mb. If one or more lesions were included in a window in the first stage of the analysis, 
then one event was counted for that window.  If no lesion was called in the first stage, the 
window was given a value of zero.  Fisher’s exact test was used to test the number of 
events across the patients of a comparison group.  We compared the lesion frequency 
within each window in both the early and late stage separately, relative to the null 
hypothesis of no lesion in a window.  The p-values of these comparisons were adjusted to 
have a false positive discovery number of 1 or less(58).  Starting and ending positions of 
any given lesion on a chromosome may be different across multiple patients. Therefore, 
to test whether a lesion was common among patients, we used the window method as a 
practical approach, considering sample size and SNP informativity rates. The 0.5Mb 
window size was determined by considering the specific array probe density (coverage of 
the genome) and SNP informativity (heterozygosity) rate for LOH detection(59).  Larger 
windows have higher probability of containing an informative SNP, but the resolution for 
detection is lower; whereas a smaller window will have higher resolution but may not 
contain informative SNPs.  Using an average SNP informativity rate of 0.26 in dbSNP 
and considering the multi-sample Illumina 33K BeadChip density, we selected a 0.5Mb 
window size in order to have 0.8 LOH detection power. We evaluated window sizes from 
0.1-1.0 Mb and obtained essentially identical results. Empirical Receiver Operating 
Curves were generated according to previously described methods(60). All the analyses 
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were carried out in Matlab (version 7.1, The Mathworks Inc.) and Statistical Analysis 
System (SAS version 9.1, SAS Institute Inc.) 
 
Results 
 
Molecular and pathology criteria defining stages of progression.  
The 42 pairs of biopsies evaluated in this study were obtained from 42 patients including 
6 women and 36 men of mean age 64.3 years (range 43 to 93). Table 1 depicts the 
participant selection criteria with regard to molecular and pathology measures for each 
stage of progression. Patients were classified using previously evaluated flow-
cytometrically purified biopsies (mean 9.64 biopsies per patient) for 17p LOH and TP53 
mutation (at baseline only), and DNA content abnormalities by flow cytometry as 
described previously(29, 43).   
   
Table 1 Molecular and pathologic stages of progression.  
 
“Early stage” BE early • No biomarker abnormalities* • 0/12 develop DNA content abnormality 
(N=12) • 0/12 develop high-grade dysplasia 
BE instability • No biomarker abnormalities* • 12/12 develop DNA content abnormality 
(N=12) • 6/12 with diagnosis of high-grade dysplasia 
Advanced BE • 17pLOH, TP53 mutation Not applicable
“Late stage” (N=10) • Aneuploidy 
EA tumor • 17pLOH, TP53 mutation Not applicable
(N=8) • Aneuploidy 
• Samples from large EA tumor mass 
EA Risk Biomarkers*  
in Follow-up
Endoscopic 
biopsies from 
Barrett’s 
epithelium 
Surgical resection 
specimens 
• Pre-operative endoscopic 
diagnosis  of small, early 
cancer; samples from 
Patient Characteristics 
at Time of Sampling 
*Biomarkers= 17pLOH (spanning TP53), TP53 mutation, DNA content abnormality (Aneuploidy and/or Increased 4N), high-
grade dysplasia  
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Genome-wide chromosome instability in different stages of neoplastic progression. 
Genome-wide chromosome instability was evaluated in patient samples representing the 
four different stages of neoplastic progression described in Table 1. Figure 1 shows the 
average percent of SNPs with copy gain or loss abnormalities, and percentage of 
informative SNPs with allelic imbalance due to copy gain, or loss of heterozygosity 
[LOH] including copy loss and copy neutral events using paired constitutive controls (see 
methods). The number of SNPs with copy gain, loss, and LOH show a highly statistically 
significant trend of increasing number of altered SNPs across each of the four 
progression stages (p<0.001). In early stages of progression, very few SNPs have copy 
number or LOH abnormalities (Figure 1). In late stages of BE progression, the frequency 
of SNP alterations increased dramatically (Figure 1). Direct comparisons of number of 
SNP probes with gain, loss and LOH between the early stages of progression (BE early 
vs. BE instability groups), and also between the late stages of BE (advanced BE and EA 
groups) did not reach p=0.01 significance level, given that the statistical power of the 
tests are small when the sample size of each group is not large. 
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Figure 1.  Percent of probes across the genome with copy gain, loss and LOH in different 
stages of neoplastic progression measured in the 33K SNP array.  * % SNP probes with 
LOH was calculated using only those SNPs that were heterozygous in the paired 
constitutive control. 
 
 
To distinguish between a high a number of small chromosomal events versus a small 
number of larger events, for example 100 regions each including 10 SNPs, compared to  
10 regions each including 100 SNPs, we assessed the size of altered chromosomal copy 
number regions. Figure 2 shows the distribution of copy gain and loss segment sizes in 
the four stages of BE progression.  
 
There was a trend for increased copy gain segment size with progression stages (p<0.01). 
However, copy gain frequency and segment size did not reach statistical significance 
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between early BE and BE instability stages, given the samples sizes of comparison 
groups (p=0.65, p=0.70 respectively, Figure 2). Similarly, the frequency and segment size 
of copy gain also did not reach statistical significance at p=0.01 between advanced BE 
and EA stages (p=0.84, p=0.04, respectively). However, when the combined early stages 
(BE early and BE instability) were compared to the combined late stages (advanced BE 
and EA), the frequency and segment size of copy gain were both significantly different 
(p<0.001). 
 
There was a statistically significant difference in the number of regions of copy loss 
between the BE early and BE instability groups (p=0.005, Figure 2). However, many of 
these regions were based on loss of a single SNP. Neither the total number of SNPs with 
loss (p=0.12, Figure 1) nor the median sizes of loss (p=0.20, Figure 2) were different in 
the two groups. Similarly, neither frequency nor segment size of copy loss reached a 
p=0.01 level of statistical significance between advanced BE and EA (p=0.04, p=0.23, 
respectively) given the sample size. However, when the combined early stages were 
compared to the combined late stages, frequency and segment size of copy loss were both 
significantly different (p<0.001).  
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Figure2.  Gain and loss size distribution of the four progression stages.  
 
 
SNP distribution patterns along the chromosome and the heterozygosity rate of specific 
SNPs affect the ability to call LOH segment sizes precisely(59). Therefore, we plotted the 
distribution of LOH using allele frequency differences between paired constitutive 
controls and BE/EA samples (|dAlleleFreq sub-ref|) for each informative probe displayed 
by chromosome in each sample (Figure 3).   
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Figure 3A. Distribution of informative SNPs with LOH (black bars) on chromosomes 1 
to 5 (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome) in 
individual samples from 42 patients (columns). Regions with no black bars represent 
either non-informative SNPs or no LOH. Patients are grouped along the x-axis into the 
four stages of neoplastic progression and the numbers along the x axis refer to individual 
patients.  
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Figure 3B. Genome wide LOH map of chromosomes 6 to 12 for individual samples 
(n=42).  The organization is the same as in Figure 3A. 
. 
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Figure 3C. Genome wide LOH map of chromosomes 13 to 22 of individual samples 
(n=42).  The organization is the same is in Figure 3A.  
 
 
Somatic copy gain, loss and LOH lesions might confer a selective advantage to the clone. 
Alternatively, a lesion may be the result of random, non-selected events arising during 
neoplastic evolution, especially in later stages of progression after inactivation of TP53. 
Therefore, we examined the frequency of each lesion across patients. The numbers of 
patients in each of the four stages are small and the results from Figures 1 and 2 indicate 
that BE early and BE instability groups have statistically similar magnitudes (albeit not 
the same) of copy gain, loss, and LOH frequencies and sizes relative to each other as 
compared with advanced BE and EA groups. Therefore, patients from the BE early and 
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BE instability groups were combined into a single early stage group in order to get more 
power for lesion detection. Also, advanced BE and EA have similar (albeit not the same) 
magnitude of instability relative to each other as compared to the two early groups. 
Therefore, the advanced BE and EA patients were combined into a late stage group and 
evaluated separately. Statistically significant levels of chromosome copy change and 
LOH events among patients are shown for early stage (supplemental Figure 1A, 1B) and 
late stage (supplemental Figure 1C, 1D).  A complete list of statistically significant 
abnormalities identified in each 0.5Mb window detected in early and late stages of 
progression are presented in supplement materials (Tables S1 and S2).  
 
We also evaluated the relationship between the significant alterations identified 
independently in genome-wide analysis of early (BE early and BE instability) and late 
(Advanced BE and EA) stages of progression. Figure 4 illustrates the relationships 
among the significant copy gain (Figure 4A), copy loss (4B) and LOH (4C) windows. Of 
the 56 0.5Mb windows identified with copy gain in late stages, only 2 of 56 (4%) also 
reached statistical significance in early stages of progression. Of the windows identified 
as reaching statistical significance in late stages, 22 of 350 (6%) copy loss and 71 of 878 
(8%) LOH events also reached statistical significance in early stages of progression. The 
specific lesions and locations that were common in both early and late stages are shown 
in Table 2. For the patients in this study, the average rate of informative SNPs on this 
array is 0.33. Thus, there is a significant probability for small segments with copy loss to 
have no informative SNPs available for LOH analysis. The LOH events listed in Table 2 
that did not reach statistical significance in the small regions of copy loss on 
chromosomes 1, 4, 10, 11, 12, 18, and 20 were mainly due to lack of informative SNPs.     
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Figure 4. Number of 0.5MB windows with chromosome lesions that reached statistical 
significance across patients in Early (BE early and BE instability) and Late (advanced BE 
and EA) stages of neoplastic progression.  Light dots: The number of 0.5 MB windows 
that reached statistical significance in early stage (BE early and BE instability) samples 
only but were not significant in late stage samples. Intersection of dots and cross 
hatched:  The number of events that reached statistical significance both in early stage 
(BE early and BE instability) and late stage (advanced BE and EA) samples. Cross 
hatched: The number of events that reached statistical significance in late stage 
(advanced BE and EA) samples only but were not significant in early stages.  
 
 
 
Lesion type [Chromosome] ( location and range in ± 0.5MB )
Gain
Loss
LOH [3] (59.8 ~ 60.8);   [9] (0.5 ~ 38.1);  [16] (77.3)
[8] (145.5);  [10] (73.5)
[1] (186.6);  [3] (59.8 ~60.8);  [4] (33.9);  [9] 
(9.0~12.1, 20.5~25.0, 28.5~30.5, 44.5); [10] (68.0);  
[11]  (38.5);  [12] (28.3);  [16]  (77.3);  [18] (64.9);  
[20] (22.0)  
Table 2. Lesions that reached statistical significance in 
both early and late stages of progression.
 
 
 
 
Late 
(328) 
 
(22) 
Late   
(807) 
Early 
(4)  
Early 
(11)  
 A: Gain B: Loss   C: LOH  
 
(71) 
Early 
(15)  
Late 
(54) (2) 
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Comparison of genome-wide SNP-based LOH to flow cytometric DNA content 
aneuploidy in unpurified, whole biopsies 
 
DNA content abnormalities as measured by flow cytometry have been reported to be 
useful for cancer risk stratification in BE(48, 61, 62). To test the ability of a SNP 
platform to detect populations of cells with abnormal DNA content, we minced each 
biopsy, divided the homogenate in half, and processed half using the multi-sample 
Illumina 33K SNP arrays and the other half by DNA content flow cytometry using our 
standard protocol and analysis as described in methods. Multiple genetic mechanisms can 
generate allelic imbalance resulting in LOH measured by allele frequency differences 
between paired constitutive controls and BE/EA samples (|dAlleleFreq sub-ref|)| 
including copy gain in a heterogenous population, copy loss and copy neutral LOH(55, 
63). Although small regions of LOH may not be detected if there are insufficient 
informative SNPs, genome-wide chromosomal instability arising in a population of cells 
would be detected by the LOH signal of a SNP-based platform, with the exception of 
balanced copy number alterations such as a pure tetraploid population or pure population 
with homozygous deletions.  We compared genome-wide LOH results obtained in 
unpurified biopsies to DNA content flow cytometry for aneuploidy detection in the same 
biopsies (Table 3).  Aneuploidy was detected by flow cytometry in 11 of 42 biopsies. A 
threshold of ≥ 1000 SNPs with LOH throughout the genome (gw-LOH), which represents 
about 9% of the average number of informative heterozygous SNPs on the 33K platform, 
provided the optimal sensitivity and specificity for discriminating flow-cytometric 
diploid and aneuploid samples. 10 of 11 (~91%) of the aneuploid populations that were 
detected by flow cytometry had ≥ 1000 SNPs with LOH. The one exception was the only 
near-diploid aneuploid sample in the study. This sample had a flow-cytometric DNA 
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content of 2.3N. Patients with near-diploid aneuploid populations are at lower risk of 
progressing to EA(61).  There were 7 samples with ≥ 1000 SNPs with LOH but which 
were diploid by flow cytometry. Six of seven samples were from patients with EA or 
advanced BE. Thus, gw-LOH has potential to be a surrogate for flow cytometric DNA 
content aneuploidy.   
 
Table 3. Comparison of SNP-based genome wide LOH relative to flow cytometric DNA 
content in unpurified, whole biopsies.  
 
DNA Content
gw-LOH 
(<1000)
gw-LOH 
(≥1000)
Diploid 24 7*
Aneuploid 1** 10
 
 *6/7 patients were advanced BE or EA. 
**2.3N near-diploid aneuploid by flow-cytometry  
 
The relationship between genome wide LOH (33K BeadChip) and stages of 
progression.  
 
We also evaluated the sensitivity and specificity of genome wide LOH in whole biopsies 
using the 33k array for distinguishing patients with or without concurrent cancer. The 
total number of informative SNPs with LOH (LOHTotal) across all 22 chromosomes was 
summed for each patient. The mean LOHTotal for early stages (BE early and BE-
instability) was 456 (standard error = 123) compared to 3445 (standard error = 587) for 
advanced stages (advanced BE and EA).  If LOHTotal was used to distinguish between 
early and late stages, we obtained an AUC of 0.91 as shown in the empirical ROC curves 
with the raw data in Figure 5. The results were essentially identical using paired samples 
for copy gain and loss.  
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Figure 5. ROC curve for separating advanced stages (advanced BE and EA) vs. early 
stages (BE or BE instability) using total genome wide LOH (AUC=0.91) or copy gain 
and loss (AUC=0.91).  
 
Finally, we compared genome wide LOH measurements to DNA content flow cytometric 
aneuploidy for sample classification of early and late stages of progression (Table 4). The 
results are promising for SNP-based assessment of aneuploidy for cancer risk in whole, 
unpurified biopsies.  
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Tissue type Diploid Aneuploid gw-LOH (<1000)
gw-LOH 
(≥1000)
BE-Early or  
BE-instability 24 0 23 1
Advanced BE 
or EA 7 11 2 16
Table 4.  Comparison of DNA content flow cytometry alone and 
genome wide LOH for discriminating progression stages.
 
 
 
 
Discussion 
 
A previous chromosome instability biomarker panel for cancer risk stratification in 
Barrett’s esophagus required Ki67/DNA content multi-parameter flow cytometric cell 
sorting for enrichment of proliferating epithelial cells, a panel of STR polymorphisms on 
chromosomes 9 and 17 for LOH analysis, and DNA content flow cytometric assessment 
of tetraploidy and aneuploidy (43). Although this chromosome instability panel 
accurately identified patients at high- and low risk for progression to EA, it required a 
constellation of technologies that are difficult to perform outside of research centers. 
Here, we report that 9p and 17p LOH could be detected in whole, unprocessed biopsies, 
and that genome-wide SNP based measures of LOH and copy number performed as well 
or better than DNA content flow cytometry for detection of aneuploidy, providing a 
significant advance towards validating the biomarkers in a clinically compatible, SNP 
DNA array platform. A similar platform might also be useful in assessing cancer risk in 
oral leukoplakia,  based on the previous panel of 9p and 3p LOH, TP53 abnormalities and 
chromosome polysomy (43). We used SNP DNA arrays on neoplastic and paired 
 27
constitutive control samples from each individual to provide better resolution for smaller 
genomic events, improve signal-to-noise ratios, and differentiate constitutive copy 
number variation from somatic genetic events that arise during neoplastic progression. 
Since DNA arrays can measure LOH, copy number, and known mutations as well as 
DNA methylation, in which bisulfite treatment produces a C→T SNP at CpG sites, this 
technology may provide a common platform to compare these biomarkers in validation 
studies to efficiently select those markers most appropriate for patient management.  
 
In this study, we demonstrated feasibility for SNP-based assessment of somatic copy 
number gain, loss and LOH in patients at different stages of neoplastic progression as 
well as a genome-wide measure of aneuploidy. Validation of a common biomarker 
platform as well as validation of reliable markers for risk stratification in BE will require 
one or more large cohort studies. The ideal cohort study would include patients at all 
levels of EA risk and the biomarker(s) would be evaluated on prospectively collected 
samples. Testing of multiple biopsies, for example, one biopsy every two cm, from each 
endoscopic procedure for a given patient will likely increase reliability because 
neoplastic clones occupy variably sized regions of a Barrett’s segment. Well designed 
cohort studies using a common platform to detect LOH, copy change, and DNA 
methylation abnormalities should be able to identify a small set of unbiased, reliable 
markers for BE risk stratification. Validated biomarkers from the cohort studies could be 
translated into a less expansive, clinically compatible SNP analysis platform, such as 
custom GoldenGate, VeraCode BeadExpress, or Pyrosequencing assays, for routine, 
large-scale sample testing in the clinical setting. New tools such as massively parallel 
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sequencing technologies are likely to significantly advance our understanding of the 
underlying somatic-genetic mechanisms in cancer, including detection of tandem 
duplications, balanced translocations or inversions, and discovery of as yet unidentified 
critical genes. However, these technologies are not yet feasible for large scale cohort 
studies or clinical application. 
 
Using paired constitutive controls, we consistently detected recurrent copy gains, losses 
and LOH in unpurified biopsies even in early benign BE that showed no evidence of 
progression to EA for a mean of 10 years. At advanced stages of progression, the 
neoplastic genome contained frequent and extensive regions of copy gain, loss and LOH, 
consistent with a recent report characterizing EA using high-density SNP arrays(2). To 
characterize chromosomal instability during neoplastic progression and identify regions 
that may contain genes useful for cancer prevention, cancer risk stratification and early 
detection, we examined chromosomal abnormalities found only in patients at early stages 
of progression, those common in patients at both early and late stages and those only 
detected in patients at late stages of progression. Only a small number of abnormalities 
were frequent in early stages of progression, and with the single exception of 
chromosome arm 9p, the sizes of chromosome abnormalities were small at early stages 
compared to late stages. Of the significant 0.5Mb windows with copy gain, loss and LOH 
identified in late stages of progression, only 4%, 6%, and 8%, respectively, also reached 
statistical significance in early stages of progression. Chromosome arm 9p was unusual in 
the sense that it acquired large regions of copy loss and LOH spanning most of the arm at 
early stages of progression. Within these large 9pLOH events we found three statistically 
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significant, distinct regions of copy loss spanning 9.0~12.1, 20.5~25.0, 28.5~30.5 Mb, 
with the most frequent being potential homozygous deletions at the CDKN2A/ARF locus, 
which have been reported previously in multiple cancer types(2, 64-67). CDKN2A 
abnormalities have been associated with large clonal expansions in BE as well as other 
conditions (14, 36, 37, 68), and may be selected in BE as part of an adaptation to a harsh 
acid reflux environment (25-28). Additionally, chromosome 9 is highly structurally 
polymorphic with more than 1000 annotated genes and has evolved many intra- and 
interchromosomal duplications(69, 70). Two other common abnormalities were 
significant in early stage BE including copy loss spanning the FHIT (3p, 59.8 ~60.6 Mb) 
and WWOX (16q, 77.3 Mb) loci, detected in paired samples in 46% and 24% of early 
stage patients. These regions have been extensively studied in EA and other cancer types 
(71-82), and recently Nancarrow et al reported these regions as the two most common 
regions of homozygous deletions in EA, detected in 74% and 35%, respectively(2). This 
is consistent with the patients with advanced BE and EA in the present study in whom we 
detected FHIT and WWOX copy loss in 78% and 56%, respectively, in the late stage 
biopsies. Other relatively small lesions that contain multiple genes reached statistical 
significance among patients at early stages such as copy gain on 8q24.3 and 10q22.1.  
 
The paradox of specific chromosomal abnormalities that appear to be selected both in 
early and late stages of progression is that these events occur too frequently in early 
stages to be sufficient for development of EA because the rate of progression to EA is 
very low in most persons with BE(43, 48, 61, 83-86). This suggests several possibilities. 
First, these early, high-frequency events might be necessary but not sufficient for 
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progression. Second, the frequent, early events might be selected as part of the adaptation 
to gastroesophageal reflux, but have relatively little involvement in progression to EA, 
and could appear in late stages as hitchhikers (“passengers”) on selected events that drive 
progression to EA. Third, they might represent regions susceptible to chromosome 
damage such as fragile sites(87) that could then hitchhike on selected abnormalities such 
as an epigenetically modified progenitor cell population(88). Regardless of mechanism, 
patients with early stage BE appear to have a low risk of progressing to, or dying of, 
EA(23, 24, 43, 48, 61, 83-86, 89, 90). Effective identification of high risk patients will be 
required to guide cancer prevention strategies in BE, focusing on patients who may 
benefit from the intervention because their risk of cancer is high, and reassuring low-risk 
patients who are unlikely to benefit from an intervention targeting only the BE mucosa. 
 
In this manuscript, we also report that frequent loss or LOH involving whole 
chromosome arms were observed in late stages of progression, including 3p, 5, 9p, 13, 
17p and 18q (Figures 1 to 3 and supplemental Figure 1, Table S2), many of which have 
recently been reported and reviewed (55), as well as in earlier low density STR 
allelotypes(45-47, 91). Large recurring regions of copy gain, loss and LOH may provide 
reproducible assessment of aneuploidy by higher density SNP platforms and this could be 
combined with an array assessment of more localized regions of copy gain, loss or LOH 
in a common platform to assess chromosomal instability for risk stratification in BE and 
other conditions. We also confirmed 17p status in the SNP arrays compared to previous 
STR results in 38 of 42 patients (90%) even though we did not use the same biopsies in 
the current study and at least two of the discordant cases could be proven to be due to 
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sampling limitations because the samples also lacked aneuploid populations that were 
present in the original biopsies (data not shown).  
 
Our study has limitations, including the relatively small sample size in each of the 
participant categories, and validation of our results will require large cohort studies. 
However, our results provide important insight into the level of chromosomal instability 
relative to stages of neoplastic progression in BE. In addition, supervised statistical  
methods could be used for sample classification, but we chose not to prematurely exclude 
or include markers from the present study because of the limited sample sizes and probe 
densities. Further, although the current SNP platforms are potentially technically limited 
in detecting a perfect 4N tetraploid population, a large, pure tetraploid clone may be rare 
in an evolving neoplastic population of cells. Despite these potential limitations, this 
study succeeded in proof of concept that LOH, copy number and aneuploidy can be 
assessed in unprocessed whole biopsies from Barrett’s esophagus using a SNP array. By 
assessing chromosome instability in premalignant and malignant stages of neoplastic 
progression, the results can guide future hypothesis-driven research to better evaluate 
genomic abnormalities for cancer risk stratification, early detection and identification of 
candidate targets for cancer prevention.  
 
In summary, our results indicate that SNP array assessment of genome-wide 
chromosomal changes that develop during neoplastic progression provide promise for 
improved EA risk stratification in patients with BE, and this hypothesis, as well as others 
based on DNA methylation, can be efficiently tested in cohort studies, using 
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prospectively accumulated biospecimens (EDRN phase 4)(92). This single-platform 
assessment of chromosome instability biomarkers might also be used to identify patients 
at high risk of developing EA for cancer prevention trials. 
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